Immunovant’s Phase 2 Failure of IMVT‑1402 Sends Stock to One‑Year Low
Immunovant’s Phase 2 flop of IMVT‑1402 for cutaneous lupus halts its autoimmune pipeline, sparking a steep stock decline and investor doubt.
3 minutes to read
IMMUNOVANT INC
Immunovant Q1 2026: $797.8M Cash, $14M R&D, 6 On-Track Indications for IMVT‑1402
Immunovant (IMVT) reports Q1 2026 results: $797.8 M cash, $14 M R&D spend, and on‑track data for IMVT‑1402 across six indications, including Graves’ disease and myasthenia gravis.
2 minutes to read
Immunovant’s Batoclimab Fails Phase‑3 Trial, Stock Slides 16% After TED Results
Immunovant’s batoclimab fails Phase‑3 thyroid eye disease trial, slashing stock and spotlighting the high risk of FcRn‑blocking immunotherapies.
3 minutes to read
Immunovant Inc. Reports Breakthrough in Graves’ Disease Treatment with Promising Remission Results
Immunovant Inc. has announced promising results for its Graves’ disease treatment, achieving durable and treatment-free six-month remission in patients, marking a potential breakthrough in the treatment of this chronic autoimmune disorder.
3 minutes to read